Tampilkan postingan dengan label pharma. Tampilkan semua postingan
Tampilkan postingan dengan label pharma. Tampilkan semua postingan

Kamis, 22 Juni 2017

Lowering drug prices by raising drug prices.

Today's Managing Health Care Costs Number is 1/6


Kaiser Health News and the New York Times have reported on the four page Trump executive order to decrease drug prices.    He's going for irony -- he will decrease drug prices by raising them.

The recommendation comes from Trump's Drug Pricing and Innovation Workgroup, which is chock full of pharma industry executives.  As Kaiser Health News reports:

To solve the crisis of high drug prices, the group discussed strengthening the monopoly rights of pharmaceuticals overseas, ending discounts for low-income hospitals and accelerating drug approvals by the Food and Drug Administration. 

So - the administration thinks that if pharma companies are able to earn more dollars in India or Brazil they will lower their prices in the US?    That's simply not how pricing works!  The pharmaceutical companies have been plenty profitable overall and that has not led to any relief of steady price inflation.  Drug companies charge what the market will pay - and allowing them higher profits in one arena doesn't simply lower prices somewhere else. New oncology and specialty drugs routinely cost over $100,000 a year, and price increases on existing medications continue to outpace inflation.

The Administration would also decrease 340b discounts to hospitals and providers who serve low income communities.   Exactly how that would help drug prices?   It would increase pharmaceutical industry profitability allowing the drug companies to lower their prices overall.   Does anyone really believe that?

There's more.   The executive order could allow pharmaceutical companies to provide marketing material to insurers and pharmacy benefit managers before FDA approval, and "use less rigorous clinical trial standards to speed drug approvals."  I can see how this could decrease value (encouraging the use of new expensive drugs with little or no benefit beyond older established drugs).  But I can't see how this will decrease cost!

The FDA released a blog post promising action to prevent brand name legal tactics that delay introduction of generic medications.  That is one element of the Trump plan that could lead to some price relief.   However, the problem we face is the cost of brand name drugs.  We should push to get faster approval for generics, and we should allow importation of generics from other developed countries when we face shortages in the US. 

But we need action to decrease the price of new medications.   There are potential answers out there:
  • Medicare could negotiate prices (prohibited by the Medicare Part D enabling legislation).
  • The FDA could consider cost in drug approval (prohibited by current rules). 
  • The National Institutes of Health could "march in" and retake patents for drugs which are priced too high
  • We could implement an excise tax on excessive prices.  We could enable payments for expensive effective medications over the period of benefit rather than "up front."  

Here are a set of recommendations from Consumer Reports

But the Trump Administration drug plan is the answer to the pharmaceutical industry's wish list. It will raise overall drug costs abroad through actions to protect patents, and it will raise overall drug costs here by cracking down on 340b discounts. 

Kamis, 02 Februari 2017

Can Trump Put a Lid on Pharma Prices?

Can Trump Put a Lid on Pharma Prices?


Today's Managing Health Care Costs Number is $325 billion

We have a drug price crisis in the United States.  Total cost of pharmaceuticals is now 1/5 of costs for many employers, and we routinely see new drugs priced at $100,000.   Some of these drugs are lifechanging (like new treatments for melanoma and hepatitis C cures), although others are only marginal improvement over existing less expensive therapy (many other cancer drugs).  Last year drug spending climbed 9% to $325 billion; it climbed 12% the previous year. Source 

Donald Trump has promised to unleash the market by slashing regulations on drug companies, but has threatened to tame drug prices through competitive bidding and his bully pulpit. 

Let's look at the underlying causes of high drug costs to consider what is likely to happen during the Trump administration.

  1. Innovation:   When a company produces a product that meets a real need - there is value to that - and the company will general price its product to reflect its value to purchasers.
  2. Chronic disease: Our population is getting older and we have more obesity and diabetes - so the prevalence of chronic disease is up. The pharmas have been effective at producing drugs that address chronic disease - so "customer retention" is high - and lifetime cost of a chronic medication is almost always more than for acute self-limited treatment .
  3. Government policy: The US is the only high income country that doesn't employ either price regulation or monopsony purchasing to keep pharma prices in check.  Pharmaceutical companies raise prices because they can
  4. Supply chain:  The supply chain in pharmacy is a mess.   The pharmaceutical companies sell to wholesalers who provide drugs to local pharmacies; pharmacy benefit managers (PBMs) negotiate prices on behalf of employers with the pharmaceutical company.  "List" prices are irrelevant - rebates are paid form the pharmaceutical company to the PBM in an utterly opaque manner - so determining the true price paid for a drug is maddeningly difficult.
  5. Moral hazard:   Insurers have employed cost sharing as a way to encourage patients as consumers to purchase drugs prudently.  But the pharmas provide coupons and even give drugs away to avoid lowering their "list" price, and fund dedicated charities to decrease patient cost share again to protect their price
  6. Social norms:  CEOs want their companies to be successful, and given mostly fixed costs of producing any given drug, price increases are the best way to gain higher margin
     

The Trump administration's proposals to decrease FDA regulation are not likely to decrease the cost of drugs.  The FDA is pretty quick with its reviews at this point - and regulatory issues are not the main development cost.   If we allow marketing of medicines with unproven efficacy that will likely increase cost - as they will all have a price tag, and some won't work and some might even be harmful.  The use of rebates and coupons makes it unlikely that patients will be able to be true "value" purchasers.

There appears to be no chance the FDA will initiate review of cost effectiveness of pharmaceutical products at this point. The FDA could allow importation of a drug from other "trusted" countries when there was a shortage or when a medication was viewed to be priced too high in the US - and this could help keep a lid on prices. This will be less effective for single source brand name drugs, where the manufacturer could limit supply to other countries where the price is lower.

Some regulation of the supply chain with full disclosure of rebates could make a difference - although that's regulation we're unlikely to see.  I also think we're unlikely to see Medicare Part D amended to allow CMS to do bulk price negotiation.  This works well for the Veteran's Administration -but that would be increasing the government role, which I see is unlikely.

Which brings us to bully pulpit.   Pharmaceutical companies (just like health plans or hospital systems) are sensitive to their public image -and they don't want to be subjects of Donald Trump's angry early morning tweets.   I think the invective around drug prices is likely to have some impact, although I worry there will be a few high profile price rollbacks (like Mylan's Epipen) and the overall costs of pharmaceuticals will continue to soar.

Kamis, 05 Januari 2017

  Bill prohibiting step therapy in NY will raise costs

Bill prohibiting step therapy in NY will raise costs


Today’s Managing Health Care Costs Number is $530 Million


New York State passed a bill prohibiting insurers and pharmacy benefit managers from requiring “step therapy,” where patients must first try a lower priced medication before they get authorization and receive insurance coverage for a higher priced medication.

The bill was passed at the end of 2016 and takes effect right now- which is a problem for health plans which have already created 2017 budgets (and set premiums)– and now face an unexpected new cost.  Actions like this encourage health plans to build “padding” into their premium rates – which make health insurance less affordable or encourage plans that strip out important benefits to cover such contingency funds.

The bill was fashioned as “consumer protection,” as it provides a better benefit without any hassle for patients whose physicians prescribe expensive medications.  However, there are tradeoffs.   An industry group says the increased cost will be $530 million. 

According to newyorkupstate.com:
The new law was hailed by the U.S. Pain Foundation.
"Patients deserve timely and medically necessary treatments without insurance companies interfering with their treatment plan," Paul Gileno, president of the U.S. Pain Foundation, said in a prepared statement.